Close Menu

NEW YORK – Thermo Fisher Scientific said on Tuesday that it has expanded its strategic partnership with Agios Pharmaceuticals to codevelop a companion diagnostic test to identify low-grade glioma patients with IDH1 and IDH2 mutations who may be eligible for Agios' investigational inhibitor vorasidenib.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.